Management of ocular surface disorders may be needed for patients who are on dupilumab to treat atopic dermatitis, according to a presentation at the American Academy of Dermatology virtual meeting.
The retrospective chart review included patients who received at least 52 weeks of dupilumab treatment or discontinued before 52 weeks due to ocular surface disorders.
Conjunctivitis and conjunctivitis-related symptoms, including red eyes, dry eyes, discharge and blepharitis, were assessed.
“Conjunctivitis is an ongoing safety concern associated with dupilumab treatment for AD,” the study
Uncategorized